Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy

ISSN
0340-6245
Date Issued
2018-09
Author(s)
Gross, Lisa
Trenk, Dietmar
Krieg, Anne
Gawaz, Meinrad
Massberg, Steffen
Baylacher, Monika
Aradi, Daniel
Stimpfle, Fabian
Hromek, Julia
Vogelgesang, Anja
Hadamitzky, Martin
Sibbing, Dirk
Geisler, Tobias
DOI
10.1055/s-0038-1667337
Abstract
 Phenotype-guided de-escalation (PGDE) of P2Y12-inhibitor treatment with an early switch from prasugrel to clopidogrel was identified as an effective alternative treatment strategy in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). The Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Genotyping Substudy aimed to investigate whether CYP2C19 genotypes correlate with on-treatment platelet reactivity (PR) in ACS patients treated with clopidogrel or prasugrel and thus might be useful for guidance of early de-escalation of anti-platelet treatment.